Učitavanje...

Second Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors In Lung Cancers

EGFR mutations identify patients who are more likely to respond to treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) than cytotoxic chemotherapy. The distinct success of the first generation EGFR TKIs erlotinib and gefitinib has been accompanied by the observati...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Yu, Helena A., Riely, Gregory J.
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3673302/
https://ncbi.nlm.nih.gov/pubmed/23411383
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!